INMB · Inmune Bio, Inc.
$2.17
+0.09 (+4.33%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's projected operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$60.23M
Shares
27.75M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | M.D., former CEO, President and CMO | $2,849,504 |
| David J. Moss | CEO and President | $1,845,179 |
| Mark Lowdell | CSO | $1,452,236 |
| Cory Ellspermann | CFO | $619,227 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $3,008,174 |
| David J. Moss | CFO | $2,722,003 |
| Mark Lowdell | CSO | $1,792,412 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $1,694,818 |
| David J. Moss | CFO | $1,589,218 |
| Mark Lowdell | CSO | $150,237 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $1,444,509 |
| David J. Moss | CFO | $1,298,169 |
| Mark Lowdell | CSO | $904,599 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $2,702,228 |
| David J. Moss | CFO | $2,631,228 |
| Mark Lowdell | CSO | $149,478 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David J. Moss | CFO | $300,000 |
| Raymond J. Tesi | CEO/President/CMO | $300,000 |
| Mark Lowdell | CSO | $138,204 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Marcia Allen | Director | Appointed | 2026-06-17 |
| Scott Juda, JD | Director | Appointed | 2026-06-17 |
| Tim Schroeder | Director | Appointed | 2026-06-17 |
| J. Kelly Ganjei | Director | Appointed | 2026-06-17 |
| David Moss | Director | Appointed | 2026-06-17 |
| Tim Schroeder | Director | Appointed | 2025-06-10 |
| Scott Juda, JD | Director | Appointed | 2025-06-10 |
| Marcia Allen | Director | Appointed | 2025-06-10 |
| J. Kelly Ganjei | Director | Appointed | 2025-06-10 |
| Raymond J. Tesi, MD | Director | Appointed | 2025-06-10 |
| Edgardo Baracchini | board of directors | Resigned | 2024-07-05 |
| Marcia Allen | director | Appointed | 2023-06-01 |
| Edgardo Baracchini, PhD | director | Appointed | 2023-06-01 |
| Scott Juda, JD | director | Appointed | 2023-06-01 |
| Tim Schroeder | director | Appointed | 2023-06-01 |
| J. Kelly Ganjei | director | Appointed | 2023-06-01 |
| Raymond J. Tesi, MD | director | Appointed | 2023-06-01 |
Key facts
CIK
1711754
CUSIP
45782T105
13F (30d)
78 filings
78 filers
Visit website
Investor relations